Nalfurafine is a kappa opioid receptor agonist and has been evaluated for uremic pruritus in 337 patients undergoing hemodialysis, demonstrating a reduction in pruritus in patients refractory to other therapies [81]. This evidence concerns the gene OPRK1 and Pruritus.